{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:45:22Z","timestamp":1773146722687,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.ygyno.2008.10.028","type":"journal-article","created":{"date-parts":[[2009,1,13]],"date-time":"2009-01-13T04:15:51Z","timestamp":1231820151000},"page":"444-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009"],"prefix":"10.1016","volume":"112","author":[{"given":"Amy D.","family":"Tiersten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet O.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon P.","family":"Wilczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"William R.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurie","family":"Markman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.10.028_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0090-8258(88)90249-1","article-title":"The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis","volume":"30","author":"Heintz","year":"1988","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0090-8258(91)90099-Q","article-title":"Patterns of pelvic and para-aortic lymph node involvement in ovarian cancer","volume":"40","author":"Burghardt","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.1988.6.2.282","article-title":"Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer","volume":"6","author":"Friedlander","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib6","first-page":"413","article-title":"Primary cytoreductive surgery for epithelial ovarian cancer","volume":"61","author":"Hacker","year":"1983","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecologic Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"332","author":"Van der Burg","year":"1995","journal-title":"NEJM"},{"issue":"24","key":"10.1016\/j.ygyno.2008.10.028_bib8","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"NEJM"},{"key":"10.1016\/j.ygyno.2008.10.028_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0090-8258(90)90361-N","article-title":"Neoadjuvant chemotherapy in stage X ovarian carcinoma","volume":"37","author":"Chambers","year":"1990","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/gyno.1994.1083","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer","volume":"53","author":"Schwartz","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/ijgc-00009577-199609000-00002","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer","volume":"6","author":"Surwit","year":"1996","journal-title":"Int. J. Gynecol. Cancer."},{"key":"10.1016\/j.ygyno.2008.10.028_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/gyno.1998.5236","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival","volume":"72","author":"Schwartz","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0090-8258(91)90335-3","article-title":"Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer","volume":"42","author":"Jacob","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0936-6555(05)80227-4","article-title":"Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma","volume":"5","author":"Lim","year":"1993","journal-title":"Clin. Oncol. R. Coll. Radiol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1006\/gyno.1998.5213","article-title":"Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients","volume":"71","author":"Vergote","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib16","first-page":"18s","article-title":"Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): A prospective randomized study\u2013Interim results","volume":"25","author":"Kumar","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2008.10.028_bib17","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#","article-title":"Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma","volume":"92","author":"Kuhn","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2008.10.028_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.1993.11.1.166","article-title":"Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma","volume":"11","author":"Nelson","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0889-8545(21)00316-8","article-title":"Intraperitoneal chemotherapy","volume":"21","author":"Schneider","year":"1994","journal-title":"Obstet. Gynecol. Clin. North Am."},{"key":"10.1016\/j.ygyno.2008.10.028_bib20","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"NEJM"},{"key":"10.1016\/j.ygyno.2008.10.028_bib21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib22","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study","volume":"10","author":"Markman","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib23","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2008.10.028_bib25","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"NEJM"},{"key":"10.1016\/j.ygyno.2008.10.028_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2007.11.002","article-title":"Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography\/computed tomography\u2014A prospective study","volume":"108","author":"Risum","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2007.11.004","article-title":"Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer","volume":"108","author":"Salani","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib30","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2006.11.002","article-title":"Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction","volume":"104","author":"Bristow","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00273393","article-title":"Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group","volume":"18","author":"DeGregorio","year":"1986","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00262740","article-title":"Pharmacokinetics of carboplatin after intraperitoneal administration","volume":"21","author":"Elferink","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.1990.8.8.1335","article-title":"Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy","volume":"8","author":"Speyer","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0090-8258(90)90131-4","article-title":"Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer","volume":"36","author":"Pfeiffer","year":"1990","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.10.028_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2004.12.005","article-title":"Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer","volume":"97","author":"Fujiwara","year":"2005","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808009372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808009372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:22:38Z","timestamp":1758770558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825808009372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0090825808009372"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.10.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}